ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 537,92
0,52%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Solid Biosciences Inc (SLDB)

  7. Solid Biosciences Inc (SLDB) Actualités

SLDB

Solid Biosciences (SLDB)

Solid Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SLDB
DateHeureSourceTitreSymboleSociété
13/06/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
12/06/202402h43Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
11/06/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLDBSolid Biosciences Inc
11/06/202422h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLDBSolid Biosciences Inc
04/06/202422h00GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
20/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SLDBSolid Biosciences Inc
15/05/202414h26Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SLDBSolid Biosciences Inc
15/05/202413h52GlobeNewswire Inc.Solid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
15/05/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLDBSolid Biosciences Inc
07/05/202413h00GlobeNewswire Inc.Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual MeetingNASDAQ:SLDBSolid Biosciences Inc
01/04/202413h45GlobeNewswire Inc.Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
27/03/202412h00GlobeNewswire Inc.Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumNASDAQ:SLDBSolid Biosciences Inc
13/03/202412h44GlobeNewswire Inc.Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
07/03/202413h00GlobeNewswire Inc.Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDNASDAQ:SLDBSolid Biosciences Inc
06/03/202414h00GlobeNewswire Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesNASDAQ:SLDBSolid Biosciences Inc
30/01/202422h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLDBSolid Biosciences Inc
20/01/202401h23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
16/01/202414h50Dow Jones NewsSolid Biosciences Gets Orphan Drug Designation for SGT-003NASDAQ:SLDBSolid Biosciences Inc
16/01/202414h00GlobeNewswire Inc.Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
08/01/202413h09GlobeNewswire Inc.Solid Biosciences Announces $109 Million Private PlacementNASDAQ:SLDBSolid Biosciences Inc
04/01/202414h00GlobeNewswire Inc.Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
07/12/202316h49Dow Jones NewsSolid Biosciences Shares Jump After FDA Fast-Tracks SGT-0003NASDAQ:SLDBSolid Biosciences Inc
07/12/202314h00GlobeNewswire Inc.Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003NASDAQ:SLDBSolid Biosciences Inc
22/11/202314h00GlobeNewswire Inc.Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
15/11/202314h51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:SLDBSolid Biosciences Inc
14/11/202322h05GlobeNewswire Inc.Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
09/11/202314h00GlobeNewswire Inc.Solid Biosciences to Participate at Jefferies London Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
08/11/202322h17GlobeNewswire Inc.Solid Biosciences Provides Third Quarter Business Update and Financial ResultsNASDAQ:SLDBSolid Biosciences Inc
02/10/202314h00GlobeNewswire Inc.Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical OfficerNASDAQ:SLDBSolid Biosciences Inc
31/08/202314h00GlobeNewswire Inc.Solid Biosciences to Participate in Citi’s 18th Annual BioPharma ConferenceNASDAQ:SLDBSolid Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SLDB

Dernières Valeurs Consultées

BIT
F12710
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés